Highly immunogenic malignant breast tumors that are sensitive to immunotherapy are characterized by a high expression of tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1) [204,205]. This evidence concerns the gene CD274 and neoplasm.